ChemRegen Press Releases

ChemRegen's blog

“Pancreatic cancer drug-sensitivity predicted by synergy of PAWI-2 and protein biomarker expression”

Potent inhibitor of pancreatic cancer stem cells that synergizes current standard of care, PAWI-2 is featured in Investigational New Drugs.

PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin β3-KRAS-dependent pancreatic cancer stem cells

 

Small molecule PAWI-2 potently ameliorates drug-resistant human pancreatic cancer stem cells, featured in Scientific Reports (a Nature research publication).

https://www.nature.com/articles/s41598-020-65804-5

 

“Pancreatic cancer drug-sensitivity predicted by synergy of PAWI-2 and protein biomarker expression”

Potent inhibitor of pancreatic cancer stem cells that synergizes current standard of care, PAWI-2 is featured in Investigational New Drugs.

Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ

Small molecule potently inhibited proliferation of hematologic cancer cell lines and promoted skeletal muscle differentiation from C2C12 myoblasts, featured in Scientific Reports (Nature.com).

Small Molecule Makes Heart Cells Out of Stem Cells

San Diego>, Calif., November 14, 2012 – Researchers at the Human BioMolecular Research Institute, Sanford-Burnham Medical Research Institute (Sanford-Burnham), and ChemRegen, Inc. have created a small molecule that convert stem cells to heart cells. Writing November 6th   in the Journal of Medicinal Chemistry, the team describes how they synthesized and tested ITD-1, a man-made, drug-like chemical that can be used to generate unlimited numbers of new heart cells from stem cells.

“Because heart disease is the leading cause of death in this country, we need to effectively replace lost heart muscle cells—called cardiomyocytes,” said Mark Mercola, Ph.D., director of Sanford-Burnham’s Muscle Development and Regeneration Program and co-author of the study. “Using a small molecule to create new heart muscle cells from stem cells is very appealing.”

FuzeBox Chalks Up Key TeleHealth Customer Wins, With FuzeBox CEO Jeff Cavins Appointed to the Board of Leading Stem Cell Research Firm, ChemRegen

FuzeBox, the global leader in real-time visual collaboration solutions, today announced a number of milestones, including new customer wins, in addition to announcing the appointment of CEO Jeff Cavins to the board of directors at ChemRegen, Inc.

Mending a broken heart — with a molecule that turns stem cells into heart cells

Researchers discovered a molecule that converts stem cells into heart cells, which could be used to replace diseased or damaged tissue in heart disease patients

Scientists Use Dynamic Medicinal Chemistry to Help Cardiac Regeneration

San Diego, Calif. (January 16, 2012) – Scientists at the Human BioMolecular Research Institute (HBRI) in San Diego, CA, and Sanford-Burnham Medical Research Institute (Sanford-Burnham) in La Jolla, CA and ChemRegen, Inc., a San Diego for-profit company focused on developing small-molecule regenerative medicines for human diseases have reported on a new set of small molecules helpful in human cardiomyocyte formation using inhibition of a biochemical signaling pathway called Wnt. The Wnt signaling pathway is a key mediator of cellular development and stem cell differentiation.

ChemRegen Awarded Small Business Grant Award from the National Institutes of Health.

San Diego, Calif. (July 3, 2011) - Scientists from ChemRegen, Inc. were awarded a Phase I STTR grant from the National Institutes of Health’s National Heart, Lung, and Blood Institute to use chemical biology to develop small molecule “toolbox” compounds that will stimulate stem cell differentiation and produce human cardiomyocytes. Ultimately, the results from this work will provide toolbox reagents for use to grow cardiomyocytes for use in a biotechnology process to treat heart disease and to improve the safety of human drugs in development.

Pages

Subscribe to RSS - ChemRegen's blog